New York Blood Center’s Project ACHIEVE and Columbia Research Unit of Columbia University announced their collaboration to advance the use of messenger ribonucleic acid (mRNA) technology in an HIV preventive vaccine study. The Phase 1 trial – HVTN 302– will be enrolling up to 108 people across 10 sites in the US to test 3 different experimental vaccines against HIV based on the mRNA technology, developed by researchers at Scripps Research and supported by The International AIDS Vaccine Initiative (IAVI).